This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Celldex, Pfizer Split Over Brain Tumor Drug

Updated with more information, stock price

NEEDHAM, Mass. ( TheStreet) -- Pfizer (PFE) walked away from a partnership with Celldex Therapeutics (CLDX) to develop the small drugmaker's brain tumor vaccine CDX-110, Celldex announced Friday.

Celldex has regained full rights to CDX-110 and says it intends to continue the drug's development. Pfizer decided to terminate the partnership over CDX-110 because the drug is "no longer a strategic priority" for the company, Celldex said.

Celldex shares were down $1.54, or 32%, to $3.24 in recent Friday trading.

Celldex licensed CDX-110 to Pfizer in April 2008. The drug is designed to treat glioblastoma multiformae, or GBM, a form of brain cancer.

A hint of acrimony between Celldex and Pfizer emerged earlier this summer over the speed and direction of CDX-110's development.

At the June annual meeting of the American Society of Clinical Oncology, Celldex CEO Anthony Marucci expressed frustration that the company couldn't move faster to start a pivotal, phase III study of CDX-110 because Pfizer was in charge of the drug's clinical development.

One prickly issue was how to design a randomized, controlled phase III study of CDX-110 in GBM patients -- a necessary requirement to get the drug approved. A previous attempt to conduct a randomized phase II study -- in which some patients receive CDX-110 and others receive a placebo or control treatment -- failed because patients were reluctant to enter a study in which there was a chance they wouldn't receive the experimental drug.

Previous phase II studies of CDX-110 have produced some promising benefits for brain cancer patients, but the number of patients treated were relatively small and the studies lacked a control arm by which treatment with CDX-110 could be compared.

A source close to Celldex says that Pfizer also likely reached the conclusion that CDX-110's commercial potential wasn't significant enough financially, especially after the merger with Wyeth. CDX-110 is designed to work only in a subset of patients who have GBM brain tumors with a variation of a more common protein receptor.

Celldex said additional data from a phase II study of CDX-110 will be presented at a medical meeting in November.

As of June 30, Celldex had $65.8 million in cash. Now that Pfizer has walked away from CDX-110, Celldex will need to use it own cash to fund the drug's future clinical trials.

--Written by Adam Feuerstein in Boston.

Readers Also Like:

Adam Feuerstein writes regularly for In keeping with TSC's editorial policy, he doesn't own or short individual stocks, although he owns stock in He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $94.31 -0.91%
FB $118.24 0.69%
GOOG $699.64 1.10%
TSLA $229.18 -1.40%
YHOO $36.02 0.01%


Chart of I:DJI
DOW 17,659.14 -91.77 -0.52%
S&P 500 2,050.11 -13.26 -0.64%
NASDAQ 4,727.0990 -36.1250 -0.76%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs